The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour-Reference-Cited by-同舟云学术

The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour

Published:2008-05 Issue:7 Volume:44 Page:972-977
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Chabot Isabelle,LeLorier Jacques,Blackstein Martin E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Economic evaluations in the Canadian Common Drug Review;Laupacis;Pharmacoeconomics,2006

2. Canadian Agency for Drugs and Technologies in Health. Timeframes for Common Drug Review procedure. ; 2007 [accessed 12.11.07].

3. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. ; 2006 [accessed 12.11.07].

4. Clinical endpoints in trials of drugs for cancer: time for a rethink?;Koopmans;BMJ,2002

5. Health Canada. Notice of Compliance with Conditions Policy. ; 2007 [accessed 12.11.07].

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review;Frontiers in Public Health;2022-01-10

2. Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors;JAMA Network Open;2020-09-28

3. Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis;Clinical Sarcoma Research;2020-08-06

4. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study;British Journal of Clinical Pharmacology;2019-07-17

5. Novel 2,4-Dimethyl-5-((E)-3-phenyl-3-oxoprop-1-enyl)-1H -pyrrole-3-carboxylic Acid Derivatives: New Leads in Cancer and Bacterial Chemotherapy;ChemistrySelect;2018-09-03